Stable glucagon formulations
AssigneePerosphere Inc.
InventorsSasha H. Bakhru, Bryan E. Laulicht, Xuan Jiang, Lirong Chen, Solomon S. Steiner
Life of this patent
Estimating the term…
Loading patent…
AssigneePerosphere Inc.
InventorsSasha H. Bakhru, Bryan E. Laulicht, Xuan Jiang, Lirong Chen, Solomon S. Steiner
Estimating the term…
Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit little or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non-aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration.
A stabilized glucagon formulation comprising glucagon dissolved in glycerin, wherein the formulation contains less than 5%, 1%, 0.5%, 0.25%, 0.1%, or 0.05%, weight by volume of water and an effective amount of a di-arginine piperazine to increase the stability of the glucagon.
A method of treating diabetes or hypoglycemia in a patient in need thereof comprising administering a stabilized glucagon formulation comprising a glucagon dissolved in glycerin, wherein the formulation contains less than 5%, 1%, 0.5%, 0.25%, 0.1%, or 0.05%, weight by volume of water, and an effective amount of a di-arginine piperazine to increase the stability of the glucagon.
Dependencies are inferred from the claim text.